MARKET

ALBO

ALBO

Albireo Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.29
-0.27
-1.63%
Closed 16:00 03/30 EDT
OPEN
16.68
PREV CLOSE
16.56
HIGH
17.20
LOW
15.46
VOLUME
77.12K
TURNOVER
--
52 WEEK HIGH
38.69
52 WEEK LOW
11.26
MARKET CAP
243.47M
P/E (TTM)
-3.2237
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALBO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALBO stock price target is 51.00 with a high estimate of 64.00 and a low estimate of 32.00.

EPS

ALBO News

More
  • Albireo advancing mid-stage study of IBAT inhibitor in NASH/NAFLD
  • Seeking Alpha - Article · 03/10 14:26
  • Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD
  • GlobeNewswire · 03/10 13:30
  • Albireo Pharma, Inc. Just Reported And Analysts Have Been Cutting Their Estimates
  • Simply Wall St. · 03/04 10:05
  • Wedbush Maintains Outperform on Albireo Pharma, Lowers Price Target to $60
  • Benzinga · 03/03 12:58

Industry

Biotechnology & Medical Research
+4.00%
Pharmaceuticals & Medical Research
+4.75%

Hot Stocks

Symbol
Price
%Change

About ALBO

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).
More

Webull offers kinds of Albireo Pharma Inc stock information, including NASDAQ:ALBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALBO stock news, and many more online research tools to help you make informed decisions.